Cardea Bio (part of Paragraf®)
San Diego, California, United States
Tell me more about Cardea Bio (part of Paragraf®)?
Research the business information of their company.
What pain points do professionals in their industry face?
Are there any recent company initiatives this company is involved in?
view 19 associated members
Cardea Bio (part of Paragraf(r)) is a San Diego-based company founded on January 1, 2019, with 19 employees. Specializing in Computers and Electronics Manufacturing and Semiconductor Manufacturing, the company has revenue of $5 million. Their focus is on digital biology, biosignal processing, and B2B operations. Cardea Bio is known for its innovative approach to cancer detection, focusing on sporadic testing for cancers.
Cardea Bio is the world’s only mass producer of biocompatible semiconductors, the BPU™ (Biosignal Processing Unit). The BPU is the first and only semiconductor capable of translating real-time streams of multiomics signals into digital information. Through the BPU™ platform, Cardea's long-term vision is to democratize access to the biosignals and insights behind the most advanced technology on our planet: Nature and biology. The Internet of Biology is that way becoming possible. Cardea is headquartered in San Diego and has additional activity in Los Angeles. Cardea is a 100% American developed and built biocompatible semiconductor technology for applications across a variety of sectors including human health, agriculture, molecular diagnostics, biotechnology, environmental monitoring, and animal health.
8969 Kenamar Dr. , San Diego, California, 92121, US
Cardea Bio (part of Paragraf®) offers the BPU(tm), a Biosignal Processing Unit, a mass-produced chip that creates a gateway between live signals in biology and the digital world. It offers direct communication with biology by translating near-real-time streams of multiomics signals into digital information, enabling direct communication with biology